VIM: Vinorelbine in Mesothelioma

Sponsor

Wales Cancer Trials Unit (Other)

Overall Status

Completed

CT.gov ID

NCT02139904

Collaborator

Pierre Fabre Laboratories (Industry)

154

Enrollment

Location

Arms

60.5

Actual Duration (Months)

2.5

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This study is for patients with malignant mesothelioma of the lung lining (called pleura) who have had previous chemotherapy with a platinum-based regimen whose disease has progressed. Malignant pleural mesothelioma (MPM) is an aggressive, frequently drug resistant, and incurable disease that is increasing in incidence in the UK and worldwide. All patients with MPM will relapse following first line chemotherapy and at present, there is no standard treatment available for patients in the second line setting. The vinca alkaloid chemotherapy drug vinorelbine has shown promising activity in a single arm UK trial. However to date, there has been no randomised evaluation of vinorelbine in mesothelioma in the second line setting. In addition, there have been no trials which have looked at underlying molecular changes in mesothelioma which may predict vinorelbine efficacy; This might allow vinorelbine to be used in patients only where there is a chance of benefit. Studies suggest that vinorelbine requires a gene called BRCA1 (shown to be absent in 38% of mesothelioma cases) in order to induce cell death in mesothelioma. The VIM trial aims to establish whether vinorelbine in patients with MPM helps them live longer and whether the BRCA1 gene is helpful in selecting patients most likely to benefit from treatment.

Patients will be randomised (1:2) to receive either active symptom control (ASC) (which is all supportive care deemed necessary for pain management excluding disease modifying treatment) or ASC with vinorelbine. Patients will continue vinorelbine treatment until evidence of disease progression (or unacceptable toxicity to the drug or patient withdrawal). If vinorelbine activity is demonstrated, we will use the results from this trial to inform the design of a future phase III trial.

Condition or Disease	Intervention/Treatment	Phase
Mesothelioma	Drug: Vinorelbine Other: Active Symptom Control	Phase 2

Study Design

Study Type:

Interventional

Actual Enrollment :

154 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

A Randomised Phase II Trial of Oral Vinorelbine as Second Line Therapy for Patients With Malignant Pleural Mesothelioma

Actual Study Start Date :

Mar 1, 2016

Actual Primary Completion Date :

Mar 17, 2021

Actual Study Completion Date :

Mar 17, 2021

Arms and Interventions

Arm	Intervention/Treatment
Placebo Comparator: Active Symptom Control Active symptom control includes palliative care and standard care methods used to manage symptoms	Other: Active Symptom Control
Active Comparator: Vinorelbine Active symptom control (ASC) as per local practice plus vinorelbine administered at a dose of 60mg/m2 orally on day 1, day 8 and day 15 on a 3- weekly cycle, incrementing to 80mg/m2 weekly on a 3-weekly cycle in the absence of any significant toxicity for subsequent cycles. Patients will continue chemotherapy until evidence of radiological progression (or unacceptable toxicity or patient withdrawal).	Drug: Vinorelbine Vinorelbine was first licensed in the UK for Non-Small Cell Lung Cancer (NSCLC) and advanced breast cancer in 1997. Vinorelbine (Navelbine®) is a semi-synthetic, third generation, vinca alkaloid. The cytotoxic effect of vinorelbine is through the disruption of mitotic spindle formation, blocking mitosis at the G2-M stage resulting in cell death. Other Names: Navelbine

Arm

Intervention/Treatment

Placebo Comparator: Active Symptom Control

Active symptom control includes palliative care and standard care methods used to manage symptoms

Other: Active Symptom Control

Active Comparator: Vinorelbine

Active symptom control (ASC) as per local practice plus vinorelbine administered at a dose of 60mg/m2 orally on day 1, day 8 and day 15 on a 3- weekly cycle, incrementing to 80mg/m2 weekly on a 3-weekly cycle in the absence of any significant toxicity for subsequent cycles. Patients will continue chemotherapy until evidence of radiological progression (or unacceptable toxicity or patient withdrawal).

Drug: Vinorelbine

Vinorelbine was first licensed in the UK for Non-Small Cell Lung Cancer (NSCLC) and advanced breast cancer in 1997. Vinorelbine (Navelbine®) is a semi-synthetic, third generation, vinca alkaloid. The cytotoxic effect of vinorelbine is through the disruption of mitotic spindle formation, blocking mitosis at the G2-M stage resulting in cell death.

Other Names:

Navelbine

Outcome Measures

Primary Outcome Measures

Overall Survival [2 years]
Anti-tumour activity of vinorelbine will be measured by overall survival, time from randomisation to death.

Secondary Outcome Measures

Progression Free Survival [2 years]
Anti-tumour activity of vinorelbine will also be measured by progression free survival. We will document time from randomisation to any disease progression and/or death, defined according to strict RECIST v1.1. Lesions will be compared with baseline measurements to assess progression
Number of serious adverse events reported [2 years]
The toxicity profile of oral vinorelbine in this setting will be used to assess safety. An independent data monitoring committee will convene and assess safety 6 months after the first patient has been randomised. If the trial is deemed safe to continue then safety will be assessed again approx every 6 months. Toxicity data will be assessed alongside serious adverse events.
BRCA1 status in blood and tumour samples [2 years]
Tumour and blood samples will be collected for future translational research. BRCA1 expression as a putative predictor of vinorelbine sensitivity will be measured primarily in the samples.

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Confirmed histological diagnosis of malignant pleural mesothelioma. The same block or 10 unstained slides should be available for translational research
Prior treatment with first-line standard platinum doublet based chemotherapy only
Evidence of disease progression according to CT scan
Life expectancy ≥ 3 months
ECOG performance status 0-2
Men or women aged 18 years or over
Willing to consent to provide blood and tissue for translational research
Measurable lesions by modified RECIST
Adequate organ function, including the following: Adequate bone marrow reserve: absolute neutrophil count (ANC) ≥ 1.5 x 109/L, WBC >3 x 109/L, haemoglobin ≥ 100g/L, platelets ≥ 100 x 109/L; adequate liver function: Bilirubin <1.5 x ULN AST/ALT 1.5- 2.5 x ULN.
Patients with reproductive potential (male or female), who are sexually active during the duration of the trial or the drug washout period, should be prepared to use two effective forms of contraception throughout their participation in the trial and for at least three months after the last dose of vinorelbine.
Patients must provide informed consent prior to any study specific procedures.

Exclusion Criteria:

Patients with a diagnosis of a second malignancy except prostate or cervical cancer in remission or patients with a diagnosis of basal cell carcinoma of the skin.
Have received treatment with an agent that has not received regulatory approval, within 30 days of study entry.
Are pregnant or breastfeeding.
Uncontrolled CNS disease.
Known contraindication or hypersensitivity to vinorelbine or other vinca alkaloids or to any of the constituents
Any disease significantly affecting absorption
Previous significant surgical resection of stomach or small bowel
Yellow fever vaccine within 30 days of consent
Previous vinca alkaloid chemotherapy
Palliative radiotherapy within the RECIST area in the 4 weeks prior to baseline CT chest up until randomisation.
Patients that are unable to swallow